Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to uncover hidden muscle weakness in early lung disease

NCT ID NCT07249567

Knowledge-focused Sponsor: Karabuk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares muscle strength, exercise ability, and oxygen use in 60 people with COPD, a condition called PRISm (which is like early-stage COPD), and healthy volunteers. Researchers will measure breathing muscle strength, arm and leg strength, and how well muscles use oxygen during exercise. The goal is to understand how PRISm affects the body compared to COPD and normal aging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand and manage breathing and muscle problems in people with early-stage lung conditions like PRISm.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with COPD and PRSIm will be included and compared with healthy controls

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the COPD group: * Being \>40 years old, * Being diagnosed with COPD, * Being clinically stable, * Volunteering to participate in the study. For the PRISm group: * Being \>40 years old, * Being diagnosed with PRISm, * Volunteering to participate in the study. For the healthy control group: * Being \>40 years old, * Volunteering to participate in the study. Exclusion Criteria: For the COPD group: * Having severe orthopedic, neurological, or cardiac diseases, * Being in a COPD exacerbation, * Having a comorbid lung disease, * Being on clinically unstable medication, * Voluntarily not participating in the study. For the PRISm group: * Being diagnosed with COPD, * Having severe orthopedic, neurological, or cardiac diseases, * Having a comorbid lung disease, * Voluntarily not participating in the study. For the healthy control group: * Having a known chronic disease, * Voluntarily not participating in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karabuk University, Physiotherapy and Rehabilitation Application and Research Center

    RECRUITING

    Karabük, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.